Yuvezzi now available through telehealth for adults with presbyopia

Tenpoint Therapeutics launched a telehealth prescribing program on November 9, 2026, that connects adults with presbyopia to eye care providers who assess whether they are candidates for carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (Yuvezzi; Tenpoint Therapeutics). The once-daily combination drop is approved by the FDA to treat presbyopia, the gradual loss of near vision that typically begins around age 45. Through the program, patients consult virtually with an optometrist or ophthalmologist, who determines whether treatment is appropriate.¹

“Presbyopia remains a universal and progressive condition that requires individualized management strategies, I’m excited that I will be able to offer my patients Yuvezzi, the first-of-its-kind eye drop well-suited for long-term use. For people seeking a reliable, lifestyle-friendly solution to manage their near vision challenges in aging eyes, Yuvezzi is a valuable and practical advancement,” Mile Brujic, OD, FAAO, of Premier Vision Group in Bowling Green, Ohio said in a news release.²

What is Yuvezzi and how does it treat presbyopia?

Yuvezzi combines 2 active ingredients to treat presbyopia: carbachol and brimonidine. Carbachol constricts the pupil, which increases depth of focus and makes it easier to see up close. Brimonidine helps prevent the pupil from dilating.³

The treatment requires just 1 drop per eye, begins working in as little as 30 minutes, and can last up to 8 hours. Yuvezzi can be used with both glasses and contact lenses. Patients who wear contact lenses should remove them before using the drop and wait at least 10 minutes before reinserting them.³

What did the BRIO-I and BRIO-II trials reveal?

Yuvezzi’s approval rested on 2 phase 3 trials, BRIO-I and BRIO-II, which together enrolled more than 800 adults with presbyopia.⁴ BRIO-I (NCT05270863) was a 3-arm crossover study of 182 patients at 15 US sites. It compared the combination with carbachol and brimonidine monotherapy and showed superiority over each component, which the FDA requires for fixed-dose combination approval.⁵

BRIO-II (NCT05135286) randomly assigned 629 participants with emmetropic phakic or pseudophakic presbyopia at 47 US sites to Yuvezzi, carbachol monotherapy, or vehicle.⁵ The combination met its prespecified primary visual acuity end points, with statistically significant near vision gains vs vehicle at every time point through 8 hours (P < .008).⁶ Reductions in pupil size were also statistically significant at all time points.⁶

The BRIO-II trial included a 12-month at-home dosing phase, and Tenpoint reported no treatment-related serious adverse events.⁶ Ocular hyperemia occurred in 2.8% of patients receiving Yuvezzi vs 10.7% of those receiving carbachol alone.³

How does the Yuvezzi telehealth program work?

The telehealth prescription program was developed as a complement, not a replacement, for receiving care from an ECP. Adults enroll in the program through orderYUVEZZI.com or by calling 800-204-3511, according to Tenpoint. To help patients make those connections, the company also introduced YUVEZZIdoctor.com, a directory of local eye care professionals.¹ A licensed eye care provider completes a remote assessment to decide whether the patient is a candidate, and prescriptions are shipped directly to eligible patients. Tenpoint stated the telehealth option is meant to sit alongside in-office eye care rather than take its place.¹ Participants will be encouraged to find or keep a nearby optometrist or ophthalmologist for routine examinations and ocular health monitoring.¹

The safety information lists iritis and hypersensitivity to any ingredient as reasons not to use the drop. It also advises caution during night driving and other low-light activities because vision may temporarily dim or darken. Patients are told to contact their doctor promptly if they develop sudden flashes, floaters, or vision loss.¹

Optometrists can prescribe Yuvezzi within their state scope of practice. Because of the telehealth channel, some patients may begin using the drop before an in-office examination. At routine visits, optometrists may need to ask about presbyopia drop use and review the low-light vision and retinal symptom counseling points in the product’s safety information.¹

“Many adults experiencing blurry close-up vision – especially those who don’t have an ophthalmologist or optometrist – may not realize that new prescription eye drops like Yuvezzi are an option to help reduce the constant need for reading glasses. Our new telehealth program gives more people a way to connect and explore whether YUVEZZI may be right for them, while reinforcing the importance of comprehensive eye care and supporting the practices that care for patients every day,” Carol Kearney, chief commercial officer of Tenpoint Therapeutics, said in the news release.¹

References

1. Tenpoint Therapeutics launches the YUVEZZI telehealth prescribing program. Tenpoint Therapeutics. News release. November 9, 2026. Accessed November 9, 2026. https://www.businesswire.com/news/home/20261109227166/en/Tenpoint-Therapeutics-Launches-the-YUVEZZI-Telehealth-Prescribing-Program

2. Tenpoint Therapeutics Ltd. announces FDA approval of Yuvezzi, the first and only combination eye drop approved to treat presbyopia. Tenpoint Therapeutics. News release. January 28, 2026. Accessed November 9, 2026. https://www.businesswire.com/news/home/20260128284402/en/Tenpoint-Therapeutics-Ltd.-Announces-FDA-Approval-of-YUVEZZI-the-First-and-Only-Combination-Eye-Drop-Approved-to-Treat-Presbyopia

3. How does Yuvezzi work? Yuvezzi. Accessed November 9, 2026. https://www.yuvezzi.com/how-yuvezzi-works

4. Stevenson S. FDA decision: Carbachol-brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results. Ophthalmology Times. January 29, 2026. Accessed November 9, 2026. https://www.ophthalmologytimes.com/view/fda-decision-carbachol-brimonidine-ophthalmic-solution-approved-for-presbyopia-following-brio-phase-3-results

5. Tenpoint Therapeutics announces positive topline data from phase 3 pivotal study, BRIO-II, of BRIMOCHOL PF for the treatment of presbyopia. Tenpoint Therapeutics. News release. January 9, 2025. Accessed November 9, 2025. https://www.businesswire.com/news/home/20250109824922/en/Tenpoint-Therapeutics-Announces-Positive-Topline-Data-from-Phase-3-Pivotal-Study-BRIO-II-of-BRIMOCHOL-PF-for-the-Treatment-of-Presbyopia